Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Merck & Co., Inc.
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
August 04, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
August 03, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
August 03, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Second-Quarter 2022 Financial Results
July 28, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Fourth-Quarter 2022 Dividend
July 26, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
July 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer
July 13, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market
June 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28
June 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
June 27, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
June 24, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children
June 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
June 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
June 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health
June 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
June 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
June 13, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference
June 08, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
June 07, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Investor Event to Highlight Oncology Portfolio and Pipeline
June 07, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Adjuvant Treatment With Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial
June 05, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Third-Quarter 2022 Dividend
May 24, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence
May 24, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
May 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)
May 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in Bank of America Securities 2022 Healthcare Conference
May 04, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer
April 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
April 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces First-Quarter 2022 Financial Results
April 28, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
April 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.